What commercialization actually looks like.
Three representative launches — each with a different commercial problem to solve.
HarvXtra Alfalfa: From novel trait to $210M strategic exit.
Reduced-lignin alfalfa was a genuinely novel trait — the first to improve forage quality, not just protect yield. Dairy producers needed proof that better digestibility translated to real milk production gains. The seed channel had little frame of reference for a quality-driven value proposition.
As launch lead, I built the commercialization strategy from regulatory approval through full-scale market entry. Designed positioning around measurable on-farm economics — digestible fiber per acre, not just yield — and built a channel story that translated a lab insight into a farmer's vocabulary.
HarvXtra became a successful forage biotech trait launch. The business grew to the point where Monsanto divested the alfalfa portfolio for $210M. Strategic-exit-level valuation, driven by a commercialization strategy that made a complex trait simple to adopt.
TruFlex Canola: Managing a transition that was years overdue.
TruFlex was supposed to replace the original Roundup Ready canola event years earlier, but regulatory delays in China kept pushing the timeline. I had to simultaneously manage the eventual RR discontinuation, an in-licensing deal for LibertyLink Canola from BASF, and early planning for next-generation canola traits.
As launch lead, I designed an extensive stewarded field trial program to demonstrate trait and germplasm performance before full approval. When the regulatory green light came, grower confidence was already built through direct on-farm experience.
TruFlex launched successfully across North America despite years of market skepticism. The pre-approval field trials turned a credibility problem into a confidence advantage — and the coordinated multi-product transition became a model for managing complex platform shifts in stewarded crops.
I first heard about the possibility of a lygus trait in 1999. More than two decades later, it was ready for market — the first commercialized trait targeting sucking pests in cotton with a unique avoidance feature. "First of its kind" means creating the category, defining the value, and teaching growers how to use it.
As launch lead, I built the commercialization strategy from scratch: positioning, stewardship program design, and grower education for a mechanism of action with little precedent. The core challenge was helping the market understand not just what ThryvOn did, but why it mattered and how it fit into existing IPM programs.
ThryvOn launched as the first commercialized trait targeting thrips and tarnished plant bug in cotton. By building the category from scratch — reframing value around pest avoidance, designing a stewardship program with no precedent, and educating growers on a novel mechanism — the launch established a new IPM standard for US cotton production.